Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | FOXO1 | Q12778 | 10/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29524773 | 1.00 | MAPT (0.52) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL29524162 | 0.90 | ACHE (0.53) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL29524925 | 0.90 | ACHE (0.51) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL25427109 | 0.90 | ACHE (0.53) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL25428351 | 0.90 | ACHE (0.51) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL29524192 | 0.90 | ACHE (0.51) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL25428434 | 0.90 | ACHE (0.51) | MAPTLMNAHTTSMN1; SMN2ACHE | |
| SCHEMBL29523736 | 0.89 | ACHE (0.49) | ACHEFOXO1PDE10A | |
| SCHEMBL25426785 | 0.89 | ACHE (0.49) | ACHEFOXO1PDE10A | |
| SCHEMBL30753996 | 0.89 | ACHE (0.65) | MAPTLMNAHTTSMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | MAPT 3209/4885LMNA 3819/4885HTT 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.